1	INTEGRATED NCDs TREATMENT AND CARE AMONG PEOPLE LIVING WITH
2	HIV/AIDS ATTENDING CARE AND TREATMENT AT A HEALTH FACILITY
3	
4	Atuganile Musyani <sup>1 2</sup> , Grace Mosi <sup>1 2</sup> , Erik Kinyenje <sup>1 2</sup> , Albertino Damasceno <sup>5</sup> , Mucho
5	Mizinduko <sup>2</sup> , Rogath Kishimba <sup>13</sup> , Meshack Shimwela <sup>4</sup> , Leonard Subi <sup>3</sup> .
6	
7	<sup>4</sup> Temeke Regional Referral Hospital
8	<sup>3</sup> Ministry of Health Community Development Gender Elderly and Children
9	<sup>1</sup> Tanzania Field Epidemiology and Laboratory Training Programme
10	<sup>2</sup> Muhimbili University of Health and Allied Sciences
11	<sup>5</sup> Eduardo Mondlane University-Maputo, Mozambique
12	

# 13 ABSTRACT

### 14 Introduction:

Persons living with HIV (PLHIV) in Tanzania now live longer due to the advancement of HIV care programs. For this reason, they are at an increased risk of developing Non-Communicable Diseases (NCDs). Despite many resources committed to HIV care programs, NCDs care is not effectively integrated into these programs. The study aimed at describing missed opportunities to diagnose and manage hypertension and diabetes and implementing and evaluating the effect of three months of preventive efforts among among PLHIV attending care and treatment centers (CTC)

### 23 Materials and methods:

We evaluated 333 PLHIV attending CTC for blood pressure and blood sugar levels. Patients who were diagnosed with high blood pressure equal to or above 140/90 mm Hg, or on treatment for hypertension and a fasting blood sugar above 7.0 mmol/L (126 mg/dl) were subjected to a small intervention aimed at increasing health literacy on the adherence to and control of their pathologies. Re-evaluation of their blood pressure and blood sugar levels was done at the end of a 3 months intervention.

30

### 31 **Results:**

Of the evaluated 333 PLHIV, 71 (21.32%) had hypertension and 9 (2.70%) had high blood sugar. 32 33 Among 177 PLHIV who never had their BP measured before, 37/177 ((20.90%) were diagnosed 34 with hypertension. The cohort group involved analysis of 76 patients with either uncontrolled hypertension or diabetes followed for three months. By the end of the 3<sup>rd</sup> month of intervention, 35 26/71 (36.6%) were able to control their blood pressure (BP < 140 SBP and < 90 DBP). The mean 36 37 blood pressure decreased from 164/99.5 mmHg to 159 /96mmHg. Of the 9 PLHIV with high blood 38 glucose levels, 5/9 (55.5%) had their blood sugar normalized at the end of the intervention. In a focused group discussion, most patients reported difficulties in controlling their BP due to the high 39 40 cost of medication and consequently poor adherence to medication.

41

## 42 **Conclusion:**

The burden of undiagnosed NCDs among PLHIV attending care and treatment clinic is remarkably
high. Interventions to address such diseases in CTC seem to work. HIV care and treatment
programs should provide integrated care that includes NCDs care.

# 46 **INTRODUCTION**

Global Non-Communicable Diseases (NCDs) burden remains unacceptably high (1). In 2016, NCDs were responsible for 41 million of the world's 57 million deaths (71%), where 44% were due to cardiovascular diseases (CVD) and 4% were due to diabetes (2). CVD and diabetes caused 31% and 3% respectively of all deaths globally (3). Deaths due to NCDs are expected to increase to 55 million by 2030 (4). In Tanzania in 2016, among 409,000 deaths, 134,970 (33%) were due to NCDs (5). Of these, (17,546) 13% and (2700) 2% were due to CVD and diabetes mellitus,

53 respectively (6).

Due to the advancement of HIV care programs, persons living with HIV (PLHIV) now live longer 54 (7). For this reason, they are at increased risk of developing Non-Communicable Diseases (NCDs) 55 such as hypertension (HTN) and type 2 diabetes mellitus (T2DM) like other persons due to aging. 56 In addition to the increased risk due to aging, the HIV disease itself and anti-retroviral treatment 57 58 (ART) use add more risk of NCDs to PLHIV (8–10). Chronic immune activation due to the virus and medication side effects are critical mechanisms that lead to this increased risk (11). 59 Cardiovascular disease is the leading cause of non-AIDS-related morbidity and mortality among 60 61 PLHIV (11). Diabetes affects PLHIV almost twice as often as persons without HIV (12-14). Patients with multiple comorbidities can benefit by providing integrated care for all the diseases 62 at a single point of care (15–17). Different studies have shown that an integrated platform of care 63 is very crucial in addressing NCDs (17–20). 64

The prevalence of HIV in Tanzania in 2018 was estimated to be at 4.6% (21). This translated into about 1.4 million children and adults living with the infection in the country. There has been a progressive decline in the number of AIDS-related deaths in the past decade with overall AIDS-

related mortality decreasing by 50%, from 48,000 deaths in the year 2010 to 24,000 deaths in theyear 2018 (21).

70

HIV care programs have many resources in contrast with NCDs care that is poorly financed and 71 72 is not effectively integrated into the HIV care programs (22,23). The country experiences a lack 73 of evidence-based care model for scaling up integrated HIV/NCDs care (2). This is due to inadequate or absence of effective monitoring and evaluation systems (poor NCD surveillance) 74 and inadequate use of health information regarding NCDs (15). The country has weak chronic 75 76 disease care health system which is not patient-centered, resulting in ineffective control of chronic diseases among all and also among PLHIV (15). There are often inadequate multi-sectoral 77 responses to the diseases, inadequate resources (human, infrastructures, and funds), poor 78 79 governance and leadership, and low capacity of health service providers in terms of knowledge, skills, and numbers (22). 80

Our project, therefore, aimed at describing missed opportunities to diagnose and care for hypertension (HTN) and diabetes (DM) among PLHIV attending CTC in Dar es Salaam, Tanzania, and implementing and evaluating hypertension and diabetes mellitus preventive efforts among these patients.

85

86

# **88 MATERIALS AND METHODS**

## 89 **Project design:**

90 This was a facility-based screening program for hypertension and diabetes among PLHIV
91 receiving care at CTC in Dar es Salaam, Tanzania. It was conducted from January to June 2020.
92

### 93 **Project setting:**

The project was carried out at CTC at Temeke Regional Referral Hospital (Temeke RRH). Temeke RRH is a public owned hospital that is located in the southern part of Dar es Salaam region, the largest commercial city located in the Eastern part of Tanzania. Although the hospital has specialized diabetic, cardiovascular, and CTC clinics, the services are not integrated. Patients who have been diagnosed with HTN or diabetes in an HIV clinic are referred for care in these separate clinics within the hospital settings.

100

### 101 **Target population:**

The target population was PLHIV aged 18 years or above attending Temeke RRH in Temeke District in Dar es Salaam, Tanzania. We used convinient sampling to select PLHIV who attended CTC within the 5 days of data collection. Clients were randomly selected based on availability at the time of interview. The project excluded pregnant women living with HIV/AIDS and patients with mental diseases.

107

## 108 **Project variable:**

Data collected involved demographic information, blood pressure and biochemical measurements(Blood glucose level and cholesterol level). The project also involved a short discussion for

exploring the factors leading to poor adherence to hypertensive and diabetic medication. The
primary outcome at various time points were missed opportunities for diagnosis and care for NCDs
among PLHIV. Secondary outcomes were control rates of hypertensive and diabetic patients at the
end of a three month intervention.

115

### **Blood pressure and glucose measurements:**

Blood pressure and glucose level were measured following the Tanzania national guidelines. 117 Blood pressure (BP) was measured by trained personnel using a standardized protocol and 118 119 validated and regularly calibrated electronic sphygmomanometers (Omron HEM-7270). Blood sugar levels were measured using rapid methods (Accu-chek®). Fasting and random blood sugar 120 level was used and diagnosis was based on Tanzania national guideline. Fasting blood glucose was 121 considered when patient reported not eating for more than 8 hours. Blood pressure was checked 122 three times, 5 minutes after arrival to the clinic, during triaging at the triage desk (approximately 123 30 minutes later), and at the consultation desk with a doctor. The mean of the three measurements 124 of blood pressure were used for diagnosis of hypertension. Hypertension and T2DM were defined 125 according to the Tanzania national guideline (9). Hypertension was defined as blood pressure (BP) 126 127 equal to or above 140/90 mmHg, T2DM was defined as raised fasting blood sugar of 7.0 mmol/L (126 mg/dl) or more or a random blood sugar equal or above 11.1 mmol/L (200 mg/dL). Blood 128 pressure control was defined as when the systolic BP was below 140mmHg and diastolic BP below 129 90 mm Hg on anti hypertension treatment. DM was defined as being controlled when fasting blood 130 glucose was below 6 mmol/L. 131

### 133 Enrolled in a follow-up group:

134 A cohort of 76 patients with HTN and T2DM/high blood glucose levels during the current project was followed for three monhs. At each clinic visit, patients received health education on 135 hypertension and DM. Individuals with hypertension were managed using a clinical and 136 137 medication management algorithm based on the Tanzania clinical guideline (9). Participants 138 diagnosed with diabetes were encouraged to do a lifestyle change. The patient's registry was developed following recommendations from the HEARTS technical package of the World Health 139 Organization (WHO) and Tanzania national guideline with some modification (10,11). A simple 140 surveillance system was developed for all patients diagnosed with HTN and T2DM. All 76 patients 141 142 had complete data and were involved in the analysis at the end of the study.

- *Figure 1:* The diagram showing the PLHIV diagnosed with hypertension, DM or both and
  enrollment into the cohort group for follow-up.
- 145

### 146 A focus group discussion:

147 A focus group discussion was conducted to ascertain participant knowledge about BP control and 148 reasons for poor blood pressure control. A convenience sample of patients was identified that 149 included 10 clients and 10 health care workers.

150

## 151 Analysis of data:

Data were entered and cleaned using Epi info version 7, and then analyzed using STATA version 153 15 for Windows (Stata Corp., College Station, TX, USA). Descriptive statistics such as median 154 (with interquartile range) and frequencies (with percentages) were used to illustrate the baseline 155 characteristics of participants with the relevant variables. A short description of qualitative

information was reported. Missing data were excluded from the analysis. Chi-square test was used 156 to compare categorical variables between intervention and non-intervention group in relation to 157 hypertension and diabetes diagnosis outcome. Fisher's exact test was used where appropriate. The 158 null hypothesis was that, there was no difference in distribution of characteristics between 159 intervention and non-intervention group. An alternative hypothesis was that, at least one 160 characteristics was related to intervention and non-intervention group. Binary logistic regression 161 was used to ascertain association between the independent and dependent variables. All 162 independent variables with a P value  $\leq 0.1$  in the bivariate analyses were included in the final 163 164 multivariable logistic model in order to identify the risk factors for getting hypertension and diabetes. All variables which attained a p-value < 0.05 was considered statistically significant. A 165 paired t-test was conducted on the measurements of 76 participants (systolic and diastolic pressure, 166 167 BMI, and fasting blood glucose levels) to determine if measurements at month three were different from those taken at baseline to ascertain the effectiveness of the intervention. 168

169

### 170 Ethical consideration:

An ethical clearance to conduct this project was obtained from the Muhimbili University of Health and Allied Sciences Institutional Research Board. Permission to conduct the study at Temeke Regional Referral Hospital was obtained from the Medical Officer In-charge. All participants gave informed consent to participate in the project after a thorough description of the study objectives and risks associated with participation. The project ensured privacy and confidentiality to all participants.

# 177 **RESULTS:**

## 178 **3.1. Demographic and Clinical Characteristics of the Study Participants.**

179 Study size:

180 A total of 335 PLHIV participated in the interview, with two (2) participants removed from the

- 181 analysis due to incomplete information.
- 182

A total of 333 patients were included in the evaluation for hypertension and blood sugar levels. 183 Demographic and clinical characteristics were compared between patients diagnosed with diabetes 184 and hypertension (intervention group) and those not diagnosed with either diseases (control group) 185 as shown in *table 1*. The median age (IQR) for the study participants was 46 (39-52) years. There 186 was a significant age difference between intervention and control group (P-value 0.02). The 187 intervention group were a bit older with a median age (IQR) of 48 (42-58) compared to the control 188 group median (IQR) age of 46 (38-51). Except for age, body mass index and waist hip ratio which 189 showed a significant difference between intervention and control group, there no significant 190 191 difference in all other variables between the two groups (*Table 1*).

192

### 193 Table 1: Demographic and Clinical characteristics of patients diagnosed and not diagnosed

194 with hypertension and diabetes among people living with HIV/AIDS attending Care and

## 195 Treatment Center in Dar es Salaam, Tanzania in 2020

Characteristics	Overall (N 222)	Intervention group (N 76	Control group (N 257	P-value
Characteristics	Overall (N 333)	(22.82%))	(77.18%))	r-value
Median age (SD)	46 (39-52)	48 (42-58)	46 (38-51)	
Age group in years, <i>n</i> (%)				
18-39	84 (25.23)	11 (11.47)	73 (28.40)	0.02
40-49	141 (42.34)	32 (42.11)	109 (42.41)	

50-75	108 (32.43)	33 (43.42)	75 (29.18)	
Marital status				
Single	72 (21.62)	13 (17.11)	59 (22.96)	0.25
Married/Cohabiting	118 (35.44)	23 (30.26)	95 (36.96)	
Divorced/Separated	87 (26.13)	23 (30.26)	64 (24.90)	
Widowed	56 (16.82)	17 (22.37)	39 (15.18)	
Residence, n (%)				
Temeke	277 (83.18)	66 (86.84)	211 (82.10)	0.33
Other districts	56 (16.82)	10 (13.16)	46 (17.90)	
Education level, n (%)				
Not educated	37 (11.11)	10 (13.16)	27 (10.51)	0.80
Primary School	236 (70.87)	55 (72.37)	181 (70.43)	
Secondary School	53 (15.92)	10 (13.16)	43 (16.73)	
College/University	7 (2.10)	1 (1.32)	6 (2.33)	
Duration since HIV Diagnosis				
$\leq$ 5 years	73 (21.92)	11 (14.47)	62 (24.12)	0.07
>5 years	260 (78.08)	65 (85.53)	195 (75.88)	
HIV Stage on diagnosis				
Stage 1	58 (17.42)	16 (21.05)	42 (16.34)	0.29
Stage 2	87 (26.13)	15 (19.74)	72 (28.02)	
Stage 3	162 (48.65)	41 (53.95)	121 (47.08)	
Stage 4	26 (7.81)	4 (5.26)	22 (8.56)	
CD4 count on diagnosis				
0-200	60 (18.02)	12 (15.79)	48 (18.68)	0.16
201-350	48 (14.41)	17 (22.37)	31 (12.06)	
351-2000	81 (24.32)	16 (21.05)	65 (25.29)	
Not documented	144 (43.24)	31 (40.79)	113 (43.97)	
Duration on ART, n (%)				
0-1 year	42 (12.61)	7 (9.21)	35 (13.62)	0.66
2-4 years	89 (26.73)	21 (27.63)	68 (26.46)	
> 5 years	202 (60.66)	48 (63.16)	154 (59.92)	

Current ART used, n (%)

First-line	297 (89.19)	67 (88.16)	230 (89.49)	0.85
Second line	12 (3.60)	3 (3.95)	9 (3.50)	
Not documented	24 (7.21)	6 (7.89)	18 (7.00)	
Viral load, n (%)				
Suppressed	289 (86.79)	66 (86.84)	223 (86.77)	0.91
High viral load	12 (3.60)	2 (2.63)	10 (3.89)	
Not documented	32 (9.61)	8 (10.53)	24 (9.34)	
Tobacco use, n (%)				
Current tobacco user	17 (5.11)	1 (1.32)	16(6.23)	0.09
Not using tobacco	316 (94.89)	75 (98.68)	241 (93.77)	
Alcohol use, n (%)				
Current alcohol users	26 (7.81)	6 (7.89)	20 (7.78)	0.97
Not using alcohol currently	307 (92.19)	70 (92.11)	237 (92.22)	
Mean Body mass index (kg/m2)	25.05 (5.50)	20.15 (5.71)	25, 20(5,55)	
(SD)	25.95 (5.70)	28.15 (5.71)	25. 30(5.55)	
Body mass index (kg/m2), n (%)				
Underweight	10 (3.00)	0 (0.00)	10 (3.89)	< 0.01
Normal	160 (48.05)	27 (35.53)	133 (51.75)	
Overweight	92 (27.63)	23 (30.26)	69 (26.85)	
Obese	71 (21.32)	26 (34.21)	45 (17.51)	
Waist Hip Ratio				
Recommended ratio	110 (33.03)	18 (23.68)	92 (35.80)	0.05
Abdominal obesity 1	86 (25.83)	27 (35.53)	59 (22.96)	
Abdominal obesity	137 (41.14)	31 (40.79)	106 (41.25)	
Physical activities, n (%)				
Met WHO Standard	86 (25.83)	29 (32.22)	57 (23.46)	0.11
Did not meet the WHO				
	247 (74.17)	61 (67.78)	186 (76.54)	

196 Overweight=BMI between 25.0 -29.9, Obese=BMI ≥30.0, HTN=BP≥140/90, Isolated Systolic HTN =Systolic

197 BP>140, diastolic BP< 90, Isolated Diastolic HTN-Diastolic BP>90, systolic BP <140, Suppressed viral load=Viral

198 load<1000 copies/MLS, High viral load=Viral load≥1000 copies/MLS, Physical activities-WHO recommendation-

- 199 An equivalent combination of moderate- and vigorous-intensity physical activity achieving at least 600 MET-
- 200 minutes, Diabetes-Fasting plasma glucose level  $\geq$  7.0 mmol/L
- 201
- 202 Overall, of 333 participants, 71/333 (21.32%) participants had hypertension and 9/333 (2.70%)
- were diabetic. Four 4/333 (1.20%) participants were diagnosed with both hypertension and
- diabetes. Of the 71 patients with hypertension, only 34/71 (47.89%) knew they had hypertension
- and only 5 (7%) were already on treatment but had not achieved blood pressure control. Over
- half of the study participants 177/333 (53.15%) have reported never having their blood pressure
- 207 measured before, and among these 37/177 (20.90%) were newly diagnosed with hypertension.
- 208 Overall, of the 9 participants with diabetics, 4/9 (44.44%) knew they had diabetes and were on
- treatment and 5/9 (66.67%) were diagnosed during the study.

210

The prevalence of hypertension was significantly higher in patients older than 40 years (32/71)(42.11) and 50 years (33/71, 43.42%) compared to the younger counterparts aged less than 39 years (11/71, 11.47%; P<0.05).

214

### 215 Univariate and Multivariate analysis:

Univariate and multivariate analyses results are shown in Table 2. All variable with crude OR of equal or more that 0.1 in the univariate analysis were subjected to multivariate analysis. In the analysis of risk factors, obese patients were 4 times as likely to have hypertension (AOR = 3.67; 95%CI: 1.64 - 8.17) compared to patients with normal body weight. This finding was significant even after controlling for other confounder including age, gender. People above 40 and 50 years were twice at risk each of getting hypertension compared to people aged below 40 years (AOR 1.76 95%CI 0.71-3.35 and AOR 2.48 95%CI 0.96-6.42 respectively). People with diabetes

- 223 mellitus were 5 times at significant risk of getting hypertension although the sample size was not
- adequate for comparison (AOR 5.30 95%CI 1.04-26.98).
- 225
- 226 Table 2: Association between risk factors and elevated blood pressure or blood glucose
- among people living with HIV/AIDS attending Care and Treatment Center in Dar es
- 228 Salaam, Tanzania in 2020

Characteristics	Crude OR	Р-	95% CI	Adjusted OR	P-value	95% CI	
Characteristics		value					
Sex							
Male	1			1			
Female	1.50	0.21	0.80-2.81	1.05	0.89	0.48-2.27	
Age group in years							
18-39	1			1			
40-49	1.79	0.13	0.85-3.80	1.76	0.22	0.71-4.34	
50-75	2.59	0.02	1.19-5.46	2.48	0.06	0.96-6.42	
Residence,							
Other districts	1						
Temeke	1.30	0.69	0.62-2.72				
Marital status							
Single	1						
Married/Cohabiting	0.98	0.96	0.46-2.12				
Divorced/Separated	1.44	0.35	0.66-3.14				
Widow/Widower	1.82	0.16	0.79-4.18				
Education level							
Primary School	1						
Not educated	0.98	0.96	0.43-2.26				
Secondary School	0.82	0.61	0.61-1.75				

College/University	0.59	0.63	0.07-5.01				
HIV Stage on diagnosis							
Stage 1	1			1			
Stage 2	0.50	0.10	0.22-1.13	0.41	0.08	0.16-1.11	
Stage 3	0.86	0.66	0.44-1.60	0.69	0.39	0.30-1.61	
Stage 4	0.15	0.04	0.01-0.84	0.07	0.03	0.01-0.72	
Duration on ART							
$\leq$ 5 years	1						
> 5 years	1.09	0.75	0.64-1.86				
Viral load							
Suppressed	1						
High viral load	0.73	0.69	0.16-3.43				
Tobacco use							
Not using tobacco	1						
Current tobacco user	0.22	0.15	0.03-1.69				
Alcohol use							
Not using alcohol	1						
Current alcohol users	1.12	0.82	0.43-3.05				
Body mass index (kg/m2)							
Underweight	Omitted			Omitted			
Normal	1			1			
Overweight	1.59	0.16	0.83-3.05	1.73	0.19	0.76-3.92	
Obese	2.93	< 0.01	1.54-5.61	3.67	< 0.01	1.64-8.17	
Physical activities (WHO)							
Met Standard	1						
Did not meet the standard	1.25	0.48	0.67-2.33				
Diabetes mellitus							
Normal blood sugar	1			1			
Diabetic	3.28	0.09	0.85-12.68	5.30	0.05	1.04-26.98	

- 229 Overweight=BMI between 25.0 -29.9, Obese=BMI ≥30.0, HTN=BP≥140/90, Isolated Systolic HTN =Systolic
- **230** BP>140, diastolic BP< 90, Isolated Diastolic HTN-Diastolic BP>90, systolic BP <140, Suppressed viral load=Viral
- 231 load<1000 copies/MLS, High viral load=Viral load≥1000 copies/MLS, Physical activities-WHO recommendation-
- An equivalent combination of moderate- and vigorous-intensity physical activity achieving at least 600 MET-
- 233 minutes, Diabetes-Fasting plasma glucose level  $\geq$  7.0 mmol/L
- 234
- All patients included in the cohort (76) had completed data and were available for analysis at the end of the 3 month study.
- 237

After three months of intervention, the mean change in blood pressure for study participants was from 164 to 159 mm/Hg for systolic blood pressure and 100 to 96 mm/Hg for diastolic blood pressure. Blood sugar level of patients who were diagnosed to be diabetic changed from the mean value of 11.96 to 9.38 mmol/L. Also for BMI, the change was from 28.9 to 27.5 kg/m2. *(Table 3)* 

Table 3: The effects of three months of preventive efforts in 76 HIV positive patients with
elevated blood pressure or blood glucose attending Care and Treatment Center in Dar es
Salaam, Tanzania in 2020

Baseline	Measurements at	P-value
measurements (mean ±	three months (mean	
SD)	± SD)	
99.52±14.23)	95.76 (12.51)	< 0.01
164.28±21.62	158±21.23	0.01
5.47±2.85	5.41±2.57	0.82
28.89±8.39	27.46±5.60	0.08
	measurements (mean ± SD) 99.52±14.23) 164.28±21.62 5.47±2.85	measurements (mean ±       three months (mean         SD)       ± SD)         99.52±14.23)       95.76 (12.51)         164.28±21.62       158±21.23         5.47±2.85       5.41±2.57

247	Results for a paired t-test showed a significant decrease in mean systolic blood pressure ( $t = 3.07$
248	w/df=81, p <0.01, 95%CI (2.01, 9.45)) and mean diastolic blood pressure (t=2.91 w/df=81, p<0.01,
249	95%CI (1.19, 6.33)). There was no statistically significant difference in mean FBG level (t=0.03
250	w/df=81, p =0.82, 95%CI (-0.45, 0.57)) and BMI (t=1.76 w/df=81, p =0.08, 95%CI (-0.18, 3.03)).
251	

Univariate and multivariate analysis were conducted to show the relationship of factors at the start of intervention with the decrease in blood pressure and blood glucose level. The factors to include in the univariate and multivariate analysis were selected based on being significant risk factors for hypertensive or diabetic. There were no factors related to decrease in blood pressure and glucose blood level at the univariate analysis, although at multivariate analysis, age above 50 years and being obese at the start of intervention were related to decrease in blood pressure level *Table 4*.

258

259 Table 4: Association between risk factors and decreased blood pressure or blood glucose

among 76 people living with HIV/AIDS after three months of intervention in a Care and

	0	-	-	0		

	Crude	Р-	95% CI	Adjusted OR	P-value	95% CI
Characteristics	OR	value				
Sex						
Male	1			1		
Female	1.50	0.21	0.80-2.81	1.22	0.55	0.63-2.37
Age group in years						
18-39	1			1		
40-49	1.57	0.64	0.24-10.49	1.78	0.14	0.83-3.82
50-75	0.96	0.97	0.16-5.93	2.27	0.04	1.04-4.96
Residence,						
Other districts	1					

261 Treatment Center in Dar es Salaam, Tanzania in 2020

Temeke	0.54	1.75	0.84—18.0			
Marital status						
Underweight	1			1		
Normal	0.66	0.49	020-2.15	1		
Overweight	0.75	0.65	0.22-2.60	1.49	0.24	0.77-2.88
Obese	Omitted			2.56	0.01	1.30-5.05
Marital status						
Single	1					
Married/Cohabiting	0.98	0.96	0.46-2.12			
Divorced/Separated	1.44	0.35	0.66-3.14			
Widow/Widower	1.82	0.16	0.79-4.18			
Physical activities (WHO)						
Met Standard	1					
Did not meet the standard	0.29	0.13	0.06-1.42	1.23	0.53	0.65-2.32

262

263

### 264 Adherence to diabetic and hypertensive medication:

Three focused group discussions were conducted, 10 participants and 10 healthcare workers were interviewed to explore the understanding of the participants on various risk factors for hypertension and diabetes. Also, barriers to care and adherence were discussed. Pre-defined questions were created to guide the discussion. After enough information was collected the discussion was stopped. Responses were documented during the focus group by one of the project implementers in a paper for reference during report writing.

271

272 Almost all participants had good knowledge of hypertension and diabetes. From the discussion,

the most reported challenges to adherence to medication were lack of money to buy medication,

274 unaffordable consultation fees, and medication side effects. Most of the participants didn't know the type of medication regimen they are taking, while others never took medication after diagnosis 275 or even after hypertensive and diabetic disease medication have been prescribed. Few reported 276 277 taking medication when they develop some hypertensive or diabetic symptoms as most other f time were asymptomatic. The main reason was the high cost of medication or feeling well even 278 after diagnosis. Additionally, other participants were diagnosed and kept on treatment for either 279 HTN or DM other than the current clinic but never reported that they were on treatment. Health 280 care workers reported the absence of a specialized NCDs clinic at the Care and Treatment Center 281 (CTC). They also have no current knowledge of the management of hypertension and diabetes to 282 PLHIV. They have reported having no access to routine physical and biochemichal checkup at the 283 clinic hence rendering them to miss patients suffering from NCDs. 284

285

# 287 **DISCUSSION**

In this project, we found that integration of hypertension (HTN) and diabetes (DM) prevention 288 efforts among PLHIV attending care is suboptimal in a care and treatment clinic. Most PLHIV 289 reported to never measured their blood pressure and some had a silent disease that was not 290 291 diagnosed at the clinic due to the absence of routine screening of NCDs among PLHIV. The risk 292 of having hypertension among PLHIV was high in obese patients and diabetic patients. The project also revealed that PLHIV with other NCDs co-morbidities do not adhere to NCDs medication due 293 294 to high medication costs and having a silent disease. Health care workers providing HIV care do not have up-to-date knowledge on hypertension and diabetic care rendering it difficult providing 295 of NCDs care among PLHIV. Close follow-up on hypertension and diabetes among PLHIV was 296 found to be productive due to a significant decrease in mean systolic and diastolic blood pressures 297 298 at the end of the follow-up period.

299

In our study, many HIV-positive were not screened for hypertension and diabetes in the facility 300 revealing missed opportunities to diagnose other co-morbidities among PLHIV. Due to the absence 301 302 of routine screening and care of hypertension and diabetes at the clinic, patients although known to have hypertension did not report on their conditions to health facilities. This is similar to the 303 results found in Malawi and other parts of Africa where there was low integration of NCDs care 304 305 in PLHIV (15,19,24). This result contradicts results obtained in another study in Tanzania which reveals the integration of care to be practiced in some health facilities with high acceptability of 306 the model (25). The main reason for these findings is probably due to HIV care settings that do not 307 mandate the clinician to provide NCDs care among PLHIV. As this has not been the practice, 308 health care providers in CTC did not have up-to-date information regarding the provision of NCDs 309

care among PLHIV similar to the findings from a study done in South Africa (26). Findings from
our study call for the country to ensure health care professionals providing HIV care to be well
trained on providing comprehensive care that also includes NCDs care apart from focusing on only
HIV services.

314

315 Hypertension is a major risk factor for heart diseases however this is not well known among PLHIV (15,27–29). Our project found the prevalence of HTN to be 21.32%. This prevalence is 316 lower compared to the estimated prevalence of 26% in the general population in Tanzania (30). 317 318 Similar findings were obtained in a study conducted in Senegal (31). The prevalence of hypertension observed in this study is higher compared to a study which was conducted in rural 319 Tanzania which found the prevalence of hypertension to be 11.6% (9,32). However, it was lower 320 321 than that reported by studies conducted elsewhere in Mbeya and Ethiopia (32,33). The results in this project could be explained due to the nature of the project which relied on convenience 322 sampling. 323

324

Obesity was found to be an important risk factor for the development of hypertension in the current 325 326 study. This finding were obtained in this study suggesting that obesity may lead to the development of hypertension. Similar findings were found in other studies conducted in Tanzania and other 327 countries in Africa (31-33). These finding could be explained by the growing evidence that 328 329 increased visceral fat in the body is a pathological depot that leadeth to accumulation of more visceral fat in tissues (34,35). Visceral fat have been linked to increased inflammatory reactions in 330 331 endothelial cells of the blood vessels due to its sensitivity to lipolysis leading to endothelial 332 dysfunction and arterial hypertension (34,35). More evidence from different studies shows that

increased prevelance of overweight and obesity has caused increased burden of hypertension
(36,37). These finding adds to the evidence that as BMI is easily measured and widely accessible
it remains to be a simple and effective tool for screening hypertension in public practice.

336

In our study, diabetes was also associated with hypertension. Similar findings were found in a study that was conducted in Northeast Ethiopia (33). These findings further add to the evidence that diabetes is a risk factor for hypertension and adds up to the burden of HIV and the need for screening diabetes for all hypertensive HIV-positive patients (38,39).

341

Furthermore, our project found a significant change in blood pressure after three months of intervention both for systolic and diastolic blood pressure showing the effectiveness of the intervention. These findings were similar to findings in a study conducted in Bangladesh although only physical and behavioral measurements were considered and not biochemical and blood pressure levels (16). Our project showed no significant change in BMI value, while a study in Bangladesh showed a significant change in the level of physical activity which might result in a change in BMI value (16).

349

This projectwas conducted in an HIV setting where normal clinic visits took place so did not result in disruption of care to PLHIV. Although risk factors were identified and added to the evidence, information cannot be generalized elsewhere in Tanzania but can be used as a model to better research studies and program implementation. Participants were not randomly selected so some findings are prone to bias, this was because the study focused on control program, or prevention program and provide concise documentation to that effect. The other important limitation is that

356 the project was implemented during the COVID-19 pandemic which affected every part of the world. In our study, it has affected the scheduled patient follow-up clinic and measurements as 357 PLHIV were among the group prone to infection hence they were given long clinic visits to avoid 358 congestion at the clinic. Few HCWs were also scheduled in shifts to attend a clinic due to lack of 359 protective gear, hence further hindering consultative services to hypertensive patients. To 360 361 overcome this we used phone calls to follow-up patients and extension of time for clinic followup to garantie that all 76 clients in the cohort managed to have second test for both blood pressure 362 and blood glucose. 363

364

# **365 CONCLUSION AND RECOMMENDATION**

366 Our project found that most HIV-positive patients are not screened for hypertension or other NCDs. On top of that, we found that health education and close follow-up using surveillance 367 database is of importance for monitoring of patients. We found also that, adherence to antidiabetic 368 and antihypertensive medication is inadequate due to the high cost of medication and lack of 369 follow-up and monitoring. Also, the project found that being obese and diabetic are the risk factors 370 371 for hypertension. Working in the government of private organization and stage four HIV disease were associated with lower risk for hypertension. Overall, our project has shown that integration 372 of NCDs care in HIV clinics is possible and health education-based intervention at health facilities 373 374 can result in positive change if practiced effectively. This method can be recommended as a promising strategy in reducing the NCD burden among PLHIV. 375

376

We recommend the integration of NCDs and HIV services in Tanzania. Also we recommend the need to strengthen health education and screening of NCDs as the prevalence continues to grow

among PLHIV and significant changes are observed with the creation of awareness. The cost of antihypertensive and antidiabetic medication needs to be afordable, especially to PLHIV. We recommend also more robust methodological studies on the integration of NCDs care among PLHIV to make evidence-based information using a big sample size with all inclusive and exclusive criteria into consideration.

## 384 ACKNOWLWDGEMENT

385 The authors wish to thank the The Centers for Disease Control and Prevention (CDC) for financial

386 support.

387

## 388 AUTHOR CONTRIBUTION:

- 389 Conceptualization: AM, GM, EM.
- 390 Data curation: AM, GM.
- 391 Formal analysis: AM, GM, EM.
- Funding acquisition: AM.
- 393 Investigation: AM.
- 394 Methodology:AM, GM, EM.
- 395 Project administration: AM.
- 396 Software: AM.
- 397 Supervision: MM, RK, AT, LB, MS.
- 398 Validation:MS . Visualization: AM.
- 399 Writing original draft: AM. Writing review& editing: AD,MM,AT
- 400
- 401
- 402
- 403
- 404
- -
- 405
- 406

### 407 **REFERENCES**

408

409	1.	Chigom E. DEVELOPMENT OF AN IMPLEMENTATION ROADMAP 2023–203	30

- 410 FOR THE GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF
- 411 NCDS 2013–203. World Health. 2020.
- 412 2. United Republic of Tanzania. Strategic and action plan for the prevention and control of
- 413 Non Communicable Diseases in Tanzania 2016-2020. 2020.
- 414 3. Redaktion D. Non-communicable diseases: Editorial. Vol. 24, Public Health Forum. 2016.
  415 69 p.
- 416 4. World Health Organization (WHO). GLOBAL ACTION PLAN FOR THE

417 PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES. 2013.

- 418 5. Of R, Death P, To DUE. UNITED REPUBLIC OF TANZANIA. 2018;2018.
- 419 6. Andrade J. United Republic of Tanzania. World Police & Paramilitary Forces. 2016;199–
  420 199.
- 421 7. TACAIDS. The United Republic of Tanzania Tanzania Commission for Aids National

422 HIV and AIDS Response Report for 2017. 2017;(June). Available from:

- 423 http://library.tacaids.go.tz/bitstream/handle/123456789/134/National HIV and AIDS
- 424 Response Report for 2017 Tanzania Mainland.pdf?sequence=1&isAllowed=y
- 425 8. Mathebula RL, Maimela E, Ntuli NS. The prevalence of selected non-communicable
- 426 disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge sub-
- 427 district, Mpumalanga province. BMC Public Health. 2020;20(1):1–10.
- 428 9. Furrer H, Hatz C, Tanner M, Battegay M, Letang E, Study K. Incidence and risk factors
- 429 for hypertension among HIV patients in rural Tanzania A prospective cohort study.

- 430 2017;630(Ci):1–14.
- 431 10. Divala OH, Amberbir A, Ismail Z, Beyene T, Garone D, Pfaff C, et al. The burden of
- 432 hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in
- 433 HIV care: consequences for integrated services. BMC Public Health. 2016;16(1):1–11.
- 434 11. IAPAC. IAPAC Protocols for the Integrated Management of HIV and Noncommunicable
- 435 Diseases [Internet]. International association of providers of AIDS care. 2018. Available
- 436 from: https://www.iapac.org/files/2018/07/IAPAC-Protocols-for-the-Integrated-
- 437 Management-of-HIV-and-Noncommunicable-Diseases\_3.pdf
- 438 12. Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of
- 439 Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population440 Based Cohort Study. PLoS One. 2012;7(9):18–22.
- 441 13. Duncan AD, Goff LM, Peters BS. Type 2 diabetes prevalence and its risk factors in HIV:
  442 A cross-sectional study. PLoS One. 2018;13(3):1–11.
- 443 14. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas : Global estimates of the
- 444 prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract [Internet].
- 445 2011;94(3):311–21. Available from: http://dx.doi.org/10.1016/j.diabres.2011.10.029
- 446 15. Pfaff C, Scott V, Hoffman R, Mwagomba B. You can treat my HIV But can you treat my
- 447 blood pressure? Availability of integrated HIV and noncommunicable disease care in
- 448 northern Malawi. African J Prim Heal Care Fam Med. 2017;9(1):1–8.
- 16. Mondal R, Sarker RC, Acharya NP, Banik PC. Effectiveness of health education-based
- 450 conventional intervention method to reduce noncommunicable diseases risk factors among
- 451 rural population. Cardiovasc Diagn Ther. 2019;9(1):30–4.
- 452 17. IAPAC Protocols for the Integrated Management of HIV and Noncommunicable

453 Diseases. 2018;(July).

454	18.	WHO. Integrated ca	are models: an overview	Internet	. Health Services Delivery

- 455 Programme. 2016. Available from: http://www.euro.who.int/en/health-topics/Health-
- 456 systems/health-services-delivery/publications/2016/integrated-care-models-an-overview-
- 457 2016
- Nigatu T. Integration of HIV and noncommunicable diseases in health care delivery in
  low- and middle-income countries. Prev Chronic Dis. 2012;9(5):9–11.
- 460 20. World Health Organization (WHO). WHO Integrating noncommunicable disease services
- into primary health care, Botswana. p. 73–168.
- 462 21. Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV DATA -2019. 2019.
- 463 22. MoHCDGEC (Tanzania Ministry of Health, Community Development, Gender E and,
- 464 Children). Strategic and Action Plan for the Prevention and Control of Non

465 Communicable Diseases in Tanzania 2016 – 2020. Dar es Salaam; 2016.

- 466 23. Patel P, Rose CE, Collins PY, Nuche-berenguer B, Sahasrabuddhe V V, Peprah E, et al.
- 467 Noncommunicable diseases among HIV-infected persons in low-income and middle-
- income countries: a systematic review and meta-analysis. 2019;32(Suppl 1):1–28.
- 469 24. Torpey K, Mastro TD. Discussion paper on how to promote the inclusion of the

470 prevention and control of noncommunicable diseases within other programmatic areas.

- 471 2016.
- 472 25. Shayo EH, Seeley J, Bukenya D, Karoli P, Jaffar S. The Acceptability of Integrated
- 473 Healthcare Services for HIV and Non-Communicable Diseases: Experiences from Patients
- and Healthcare Workers in Tanzania. Res Sq [Internet]. 2021;1–22. Available from:
- 475 https://www.researchsquare.com/article/rs-796756/latest.pdf

- 476 26. Godongwana M, Wet-billings N De, Milovanovic M. The comorbidity of HIV,
- 477 hypertension and diabetes : a qualitative study exploring the challenges faced by
- 478 healthcare providers and patients in selected urban and rural health facilities where the
- 479 ICDM model is implemented in South Africa. 2021;3:1–15.
- 480 27. Global status report on noncommunicable diseases. 2010;
- 481 28. Mse YX, Chen X, Mse KW. Global prevalence of hypertension among people living with
- 482 HIV : A Global prevalence of hypertension among people living with HIV : a systematic
- 483 review and. J Am Soc Hypertens [Internet]. 2017;(June). Available from:
- 484 http://dx.doi.org/10.1016/j.jash.2017.06.004
- 485 29. Mayige M, Kagaruki G, Ramaiya K, Swai A. Non communicable diseases in Tanzania : a
  486 call for urgent action. 2012;14(2):1–12.
- 487 30. WHO. Mongolian STEPS survey on the prevalence of noncommunicable disease and
- 488 injury risk factors 2009 [Internet]. WHO Library. 2010. Available from: internal-
- 489 pdf://202.115.27.218/Mongolia\_2013\_STEPS\_Report.pdf%0Ahttps://www.who.int/ncds/
- 490 surveillance/steps/Mongolia\_2013\_STEPS\_Report.pdf
- 491 31. Africa W, Id NAB, Seydi M, Doye IN, Toure M, Sy P, et al. Increasing prevalence of
- 492 hypertension among HIV-positive and negative adults in Senegal , 2018;1–14.
- 493 32. Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al.
- 494 Magnitude and risk factors of non-communicable diseases among people living with HIV
- 495 in Tanzania: A cross sectional study from Mbeya and Dar es Salaam regions. BMC Public
- 496 Health. 2014;14(1):1–9.
- 497 33. Fiseha T, Belete AG, Dereje H, Dires A. Hypertension in HIV-Infected Patients Receiving
  498 Antiretroviral Therapy in Northeast Ethiopia. 2019;2019.

- 499 34. Khan M, Joseph F. Adipose Tissue and Adipokines: The Association with and Application
  500 of Adipokines in Obesity. Scientifica (Cairo). 2014;2014:1–7.
- 501 35. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of
- adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and
- subcutaneous abdominal adipose tissues of obese humans. Endocrinology.
- 504 2004;145(5):2273–82.
- 505 36. Landi F, Calvani R, Picca A, Tosato M, Martone AM, Ortolani E, et al. Body mass index
- is strongly associated with hypertension: Results from the longevity check-up 7+ study.
- 507 Nutrients. 2018;10(12):1–12.
- 508 37. Chen Y, Liang X, Zheng S, Wang Y, Lu W. Association of body fat mass and fat
- distribution with the incidence of hypertension in a population-based Chinese cohort: A
- 510 22-year follow-up. J Am Heart Assoc. 2018;7(6):1–9.
- 511 38. Spollett GR. Hyperglycemia in HIV / AIDS. :163–6.
- 512 39. Mayige M, Kagaruki G, Ramaiya K, Swai A. Non communicable diseases in Tanzania: A
- call for urgent action. Tanzan J Health Res. 2011;13(5 SUPPL.ISS):1–11.